Plaintiffs Urge Conn. Appellate Court to Allow $25 Million Asbestos Talc Verdict

Plaintiffs in a Connecticut case urge the appellate court to uphold a $25 million verdict against Johnson & Johnson, claiming the trial court correctly limited J&J's expert testimony and instructed the jury on liability. They argue evidence shows J&J's Baby Powder caused their injuries.

Original reporting

harrismartin.com

Published Nov 2, 2026, 9:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 2, 2026, 9:24 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Plaintiffs Urge Conn. Appellate Court to Allow $25 Million Asbestos Talc Verdict — source image — Source · harrismartin.com

Decision brief

The 30-second read

$JNJBearishLow

Why it matters

The legal development introduces fresh risk for JNJ, possibly affecting its stock price and prompting re‑evaluation of liability exposure.

Market read

Legal risk to a large, widely held stock; relevance primarily for equity traders and risk managers monitoring JNJ.

What to watch

Potential insurance coverage for the verdict and JNJ's strong cash position could mitigate the financial impact.

Relevance 6/10Novelty 6/10Timing: today

Background

The article reports a new appellate filing by plaintiffs seeking to uphold a $25 million verdict related to Johnson & Johnson's talc products.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJBearishMedium confidence

Context

Plaintiffs filed an appeal to keep a $25 million asbestos talc verdict against Johnson & Johnson, introducing fresh litigation risk for the company.

Expected impact

likely downward pressure as the market prices in potential payout and reputational risk

Evidence & confidence

A new appellate filing on a sizable verdict adds uncertainty; investors typically react negatively to fresh legal exposure.

Market effects

Sector

May heighten scrutiny on consumer‑goods and pharma companies facing product liability claims.

Regional

Limited to U.S. markets where JNJ trades; no broader regional effect.

Global

Minimal; primarily relevant to investors tracking JNJ and similar liability‑prone firms.

Counterpoint

What could challenge this read

Some investors may view the appeal as a procedural step unlikely to overturn the verdict, maintaining confidence in JNJ's fundamentals.

Key entities

Company
Johnson & Johnson
U.S.-listed healthcare conglomerate facing talc litigation.
Individuals
Plaintiffs (Evan C. Plotkin and Martha Barry)
Litigants seeking to maintain the verdict against JNJ.

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2